Ambeed.cn

首页 / 抑制剂/激动剂 / / DNA-PK / Compound 401

2-吗啉基-4H-嘧啶并[2,1-a]异喹啉-4-酮 /Compound 401 {[allProObj[0].p_purity_real_show]}

货号:A279135

Compound 401 is a DNA-PK synthetic inhibitor with IC50 of 0.28 μM, also targets mTOR.

Compound 401 化学结构 CAS号:168425-64-7
Compound 401 化学结构
CAS号:168425-64-7
Compound 401 3D分子结构
CAS号:168425-64-7
Compound 401 化学结构 CAS号:168425-64-7
Compound 401 3D分子结构 CAS号:168425-64-7
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Compound 401 纯度/质量文件 产品仅供科研

货号:A279135 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]
JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]
BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]
J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]
PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]
更多 >
产品名称 DNA-PK 其他靶点 纯度
PI-103 ++

DNA-PK, IC50: 23 nM

99%+
CC-115 +++

DNA-PK, IC50: 0.013 μM

mTOR 98+%
Samotolisib 99%+
NU 7026 +

DNA-PK, IC50: 0.23 μM

PI3K 98+%
PIK-75 HCl ++++

DNA-PK, IC50: 2 nM

99%+
PP121 +

DNA-PK, IC50: 60 nM

VEGFR,PDGFR 99%+
KU-0060648 ++++

DNA-PK, IC50: 5 nM

98%
KU-57788 +++

DNA-PK, IC50: 14 nM

99%+
LTURM34 ++

DNA-PK, IC50: 0.034 μM

98%+
SF2523 +++

DNA-PK, IC50: 9 nM

99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

Compound 401 生物活性

描述 DNA-dependent protein kinase (DNA-PK) is a key enzyme involved in the repair of DNA double strand breaks (DSBs). Compound 401 is a synthetic inhibitor of DNA-PK (IC50 = 0.28 μM) that also targets mTOR (IC50 = 5.3 μM) but not p110α/p85α PI3K in vitro[3]. Compound 401 inhibited mTOR activity in Raptor immunoprecipitates by 67% or 78% at 5 μM or 10 μM, respectively. In serum-starved Rat-1 fibroblast, 401 (10 μM) nearly completely decreased the phosphorylation of both S6K1 Thr389 and Akt Ser473 but with little effect on PI3K activity. In TSC1/cells, proliferation was strongly inhibited when exposed to 401 for 1 day (54%) or 2 days (84%). Growth inhibition by 401 was dose-dependent with a half-maximal effect at roughly 2 μM which is due in part to suppression of mTORC2/Akt signaling[3].

Compound 401 参考文献

[1]Ballou LM, Selinger ES, et al. Inhibition of mammalian target of rapamycin signaling by 2-(morpholin-1-yl)pyrimido[2,1-alpha] isoquinolin-4-one. J Biol Chem. 2007 Aug 17;282(33):24463-70.

[2]Griffin RJ, Fontana G, et al. Selective benzopyranone and pyrimido[2,1-a] isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro. J Med Chem. 2005 Jan 27;48(2):569-85.

[3]Ballou LM, Selinger ES, Choi JY, Drueckhammer DG, Lin RZ. Inhibition of mammalian target of rapamycin signaling by 2-(morpholin-1-yl)pyrimido[2,1-alpha]isoquinolin-4-one. J Biol Chem. 2007 Aug 17;282(33):24463-70

Compound 401 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.55mL

0.71mL

0.36mL

17.77mL

3.55mL

1.78mL

35.55mL

7.11mL

3.55mL

Compound 401 技术信息

CAS号168425-64-7
分子式C16H15N3O2
分子量 281.309
别名
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Sealed in dry,2-8°C

溶解度

DMSO: 9 mg/mL(31.99 mM),配合低频超声,并水浴加热至45℃助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方
Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。